Invention Grant
US09533962B2 (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
有权
（2R，4R）-5-（5'-氯-2'-氟联苯-4-基）-2-羟基-4 - [（5-甲基恶唑-2-羰基）氨基]戊酸
![(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid](/docs/US/2017-01-03/US09533962B2/abs.jpg.600x600.jpg)
- Patent Title: (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
- Patent Title (中): （2R，4R）-5-（5'-氯-2'-氟联苯-4-基）-2-羟基-4 - [（5-甲基恶唑-2-羰基）氨基]戊酸
-
Application No.: US15042391Application Date: 2016-02-12
-
Publication No.: US09533962B2Publication Date: 2017-01-03
- Inventor: Melissa Fleury , Adam D. Hughes , Anne-Marie Beausoleil , Erik Fenster , Venkat R. Thalladi , Miroslav Rapta
- Applicant: THERAVANCE BIOPHARMA R&D IP, LLC
- Applicant Address: US CA South San Francisco
- Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee: Theravance Biopharma R&D IP, LLC
- Current Assignee Address: US CA South San Francisco
- Agent Jeffrey A. Hagenah; Wendy Petka
- Main IPC: C07D263/34
- IPC: C07D263/34 ; A61K31/421 ; A61K9/48 ; C30B29/54 ; C30B7/14 ; A61K47/12
![(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid](/abs-image/US/2017/01/03/US09533962B2/abs.jpg.150x150.jpg)
Abstract:
In one aspect, the invention relates to a compound of the structure: or a pharmaceutically acceptable salt thereof, and a crystalline form of this compound, having neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising this compound; methods of using this compound; and processes for preparing this compound.
Public/Granted literature
Information query
